Literature DB >> 12904892

The SCID mouse model: novel therapeutic targets - lessons from gene transfer.

Matthias Pierer1, Ulf Müller-Ladner, Thomas Pap, Michel Neidhart, Renate E Gay, Steffen Gay.   

Abstract

The hallmark of rheumatoid arthritis (RA) is progressive destruction of the joints, preceded and accompanied by synovial hyperplasia and chronic inflammation. Spontaneous and induced animal models of RA reflect predominantly the inflammatory aspects of the disease. To reproduce the destruction of cartilage and bone mediated by an activated synovium, it was desirable to develop models that allow the dissection of cellular and molecular components derived from human tissue. The SCID mouse co-implantation model of human RA focuses on RA synovial fibroblasts (RA-SF) and their role in cartilage destruction. The model has provided the best evidence that RA-SF contribute significantly to matrix degradation, even in the absence of human lymphocytes and macrophages, since highly purified RA-SF invade the co-implanted normal human cartilage. Moreover, it became clear that they maintained their aggressive phenotype over long periods of time, particularly at sites of invasion into the co-implanted human cartilage. Targeting different signaling molecules, cytokines and matrix-degrading enzymes by soluble receptors, antagonists or negative mutants in the SCID mouse model of RA has implicated many of them in the mechanisms leading to cartilage destruction. However, since inhibition of a single molecule or pathway is not sufficient to inhibit the aggressive behavior of RA-SF it appears necessary to co-express in the synoviocytes genes for two or even more antagonists of e.g. cytokines, matrix-degrading enzymes or molecules interfering specifically with signaling pathways involved in the apoptosis of RA-SF. Based on the recent observation that the L1 (line-1) endogenous retroviral element appears responsible for the cytokine- independent activation via the MAPK p38delta, the current understanding of disease pathogenesis suggests that both the cytokine-dependent as well as the cytokine-independent pathways of joint destruction must be inhibited. Modulation of both pathways by gene transfer approaches in the SCID mouse model is a feasible method aimed at identifying novel targets for the prevention of cartilage destruction in RA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904892     DOI: 10.1007/s00281-003-0126-2

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  6 in total

Review 1.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

2.  TP53 mutations coincide with the ectopic expression of activation-induced cytidine deaminase in the fibroblast-like synoviocytes derived from a fraction of patients with rheumatoid arthritis.

Authors:  H Igarashi; J Hashimoto; T Tomita; H Yoshikawa; K Ishihara
Journal:  Clin Exp Immunol       Date:  2010-05-10       Impact factor: 4.330

Review 3.  Mechanisms of tissue damage in arthritis.

Authors:  Stephan Blüml; Kurt Redlich; Josef S Smolen
Journal:  Semin Immunopathol       Date:  2014-09-12       Impact factor: 9.623

4.  The 3rd International Meeting on Gene Therapy in Rheumatology and Orthopaedics.

Authors:  Christopher H Evans; Steven C Ghivizzani; Elvire Gouze; John J Rediske; Edward M Schwarz; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2005-10-28       Impact factor: 5.156

5.  Rheumatoid synovial fibroblasts differentiate into distinct subsets in the presence of cytokines and cartilage.

Authors:  Adam P Croft; Amy J Naylor; Jennifer L Marshall; Debbie L Hardie; Birgit Zimmermann; Jason Turner; Guillaume Desanti; Holly Adams; Adrian I Yemm; Ulf Müller-Ladner; Jean-Michel Dayer; Elena Neumann; Andrew Filer; Christopher D Buckley
Journal:  Arthritis Res Ther       Date:  2016-11-18       Impact factor: 5.156

6.  Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.

Authors:  Astrid Jüngel; Caroline Ospelt; Mark Lesch; Melissa Thiel; Teresa Sunyer; Olivier Schorr; Beat A Michel; Renate E Gay; Christoph Kolling; Craig Flory; Steffen Gay; Michel Neidhart
Journal:  Ann Rheum Dis       Date:  2009-06-03       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.